Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Series A Financing
Oranda Therapeutics Secures Series A Funding for Rare Disease Therapies
Details : The proceeds will be used for the commercialisation of novel medicine undergoing evaluation for treatment of hyperphagia in patients with Prader-Willi syndrome (PWS).
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
November 12, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?